| 초록 |
Objectives: Recombinant human erythropoietin (rhEPO) is an erythropoiesis-stimulating agent (ESA) commonly used in the treatment of anemia for chronic kidney disease (CKD) patients. Interestingly, rhEPO is known to have various pleiotropic effects in addition to increasing hemoglobin (Hb) levels. Here, we aimed to explore whether the improvement of anemia through rhEPO administration has an effect on body fluids or nutritional status. Methods: The patients with CKD 4 or 5 who have Hb of less than 10 g/dL were enrolled in the study (n=30). The patients received subcutaneous injections of 6,000 ~ 10,000 units of rhEPO-alpha once every 2~4 weeks for 3 months. We used bioimpedance to estimate body fluid excess (OH, overhydration; ROH, relative overhydration) and nutritional status (PhA, phase angle). We conducted blood tests including brain natriuretic peptide, albumin, creatinine, ferritin, and transferrin saturation. Furthermore, we measured jugular vein (JV) distensibility through ultrasonography. Results: Study results showed that Hb elevation was significantly associated with a decrease in ROH (r= -0.264, p=0.043). Moreover, it was significantly associated with an increase in PhA (r=0.292, p=0.025) (Table 1). During ESA treatment, as Hb increased, serum ferritin decreased (123.10 to 88.35 g/dL, p=0.010), while creatinine increased (2.98 to 3.15 g/dL, p=0.001) with statistical significance (Table 2). Conclusions: Our study demonstrated that anemia improvement during ESA treatment decreased body fluid volume and increased nutritional status. The results suggest that in addition to anemia correction, the ESA treatment may provide the benefits of reducing body fluid excess and improving nutrition. |